The United States government has funded a sprawling network of more than 120 biological laboratories across more than 30 countries, including over 40 facilities in Ukraine. These sites, long justified as frontline defenses against naturally occurring pandemics and remnants of Cold War weapons programs, are now the center of an intense transparency battle in Washington. In June 2026, outgoing Director of National Intelligence Tulsi Gabbard declassified internal records detailing these operations, alleging that previous administrations intentionally covered up the scope of these facilities and allowed dangerous pathogen experiments to proceed with minimal oversight.
The disclosure marks a major shift in public messaging. For years, officials dismissed concerns over overseas biological research as foreign disinformation. The new intelligence confirms that the U.S. government has directed billions of dollars toward foreign labs handling highly contagious agents. While federal agencies maintain these programs protect global health, the lack of centralized tracking and the presence of these labs in active war zones have triggered urgent national security questions. For an alternative view, see: this related article.
From Threat Reduction to Pathogen Escalation
The origins of the overseas network belong to a different geopolitical era. Following the collapse of the Soviet Union, the U.S. launched the Cooperative Threat Reduction program. The primary objective was straightforward. Washington wanted to secure loose nuclear materials and safely dismantle the massive, decaying Soviet biological warfare apparatus scattered across former republics like Ukraine and Georgia.
Over two decades, the mission drifted. What began as an effort to lock down dangerous samples evolved into a permanent fixture of international scientific funding. The Pentagon, the National Institutes of Health, and the U.S. Agency for International Development became major patrons of foreign research institutes. American tax dollars built modern containment facilities and trained foreign scientists to isolate, sequence, and study local diseases. Further analysis on the subject has been published by The New York Times.
Supporters argue that this footprint is altruistic. By placing diagnostic labs directly in the regions where exotic diseases naturally emerge, public health agencies can identify outbreaks before they reach American shores. If an unusual strain of avian influenza emerges in Eastern Europe or Southeast Asia, local labs funded by Washington can sequence the genome immediately, sharing the data globally.
The mechanism relies on a delicate balance. To study a virus, you must possess it. To anticipate how it might mutate, some researchers argue you must nudge it along in a lab setting. This is where peaceful public health surveillance blurs into what critics call unacceptable risk.
The Blind Spots of Foreign Oversight
The central revelation from the newly declassified material is not just that these laboratories exist, but that Washington fundamentally lost track of what was happening inside them. A major federal audit revealed that between 2014 and 2023, the U.S. government spent more than $1.4 billion on biological research outside the United States. Despite this massive expenditure, federal watchdogs could not accurately determine how many potentially enhanced pandemic pathogens were being modified under these grants.
Consider how these projects are managed on the ground. A U.S. agency awards a grant to a foreign university or state-run health department. The local facility is bound by the terms of the contract, but physical inspections by American officials are rare. The host country retains ownership of the building, while day-to-day operations are handled by local staff who answer to their own governments, not to Washington.
This decentralized structure creates massive accountability gaps. The National Institutes of Health previously admitted that U.S.-funded experiments involving bat coronaviruses at the Wuhan Institute of Virology violated grant conditions by making the viruses significantly more infectious. While federal officials maintain that those specific experiments did not trigger the global pandemic, the incident exposed a structural flaw. Once money leaves American shores, strict compliance becomes an illusion.
The danger is amplified when these facilities operate in politically unstable environments. The declassified intelligence explicitly notes that more than 40 U.S.-supported laboratories are located in Ukraine, a nation locked in a devastating war with Russia. Internal intelligence products reveal that analysts repeatedly warned that these sites housed hazardous pathogens and were highly vulnerable to Russian military advances, accidental shelling, or outright seizure.
The Bipartisan Crackdown on Pathogen Research
The political fallout in Washington has moved beyond typical partisan bickering. A growing coalition of lawmakers and intelligence officials argue that the biological research establishment operates with dangerous autonomy. The momentum culminated in an executive order signed by President Donald Trump that completely prohibits federal funding from supporting any virus enhancement or gain-of-function research in foreign nations that lack rigorous, independent oversight.
Gain-of-function research involves altering an organism to give it new abilities, such as making a virus more transmissible among humans or resistant to existing vaccines. Proponents claim this work is essential for developing preemptive countermeasures. Critics view it as biological roulette.
+-----------------------------+------------------------------------+---------------------------------------+
| Research Type | Primary Goal | Disclosed Risk Factor |
+-----------------------------+------------------------------------+---------------------------------------+
| Disease Surveillance | Mapping local pathogen variants | Low; relies on observational data |
| Biosafety Training | Securing existing viral samples | Moderate; requires physical security |
| Gain-of-Function Alteration | Enhancing transmissibility/virulence| High; potential for accidental escape |
+-----------------------------+------------------------------------+---------------------------------------+
The executive order aims to cut off the money supply for the highest-risk experiments. Enforcing the ban, however, requires a complete overhaul of how the intelligence community monitors scientific institutions. Director Gabbard issued new directives forcing intelligence agencies to aggressively gather data on overseas clinical trials and pathogen manipulation projects. The early results of this collection effort have already raised serious ethical and financial alarms within the national security apparatus.
Breaking the Circle of Denial
For four years, the public conversation around international biolabs was broken. In early 2022, any mention of U.S.-funded laboratories in conflict zones was routinely dismissed by political figures as a conspiracy theory or an adoption of foreign propaganda. The knee-jerk reaction from Washington was to deny everything rather than explain the complex reality of threat reduction programs.
That policy of absolute denial has backfired. By hiding the routine, defensive nature of these programs behind a wall of classification, the government created a vacuum. Adversaries filled that vacuum with wild claims of ethnic bioweapons and genetically modified super-soldiers. When the truth finally emerges—that the U.S. does indeed fund scores of labs handling dangerous pathogens—the public feels vindicated in its skepticism.
The reality is less cinematic but far more troubling than a Hollywood bioweapon plot. The issue is not a secret cabal engineering targeted plagues. The issue is bureaucratic inertia, a complete lack of centralized federal tracking, and a scientific community that convinced itself that the pursuit of knowledge justified the risk of an accidental pandemic.
The declassification of the 120 labs is an aggressive attempt to force a hard reset. Washington can no longer pretend these facilities do not exist, nor can it continue to hand out billions of dollars to foreign labs without knowing exactly what pathogens are being modified inside their walls. The administrative review will conclude, leadership will change, but the fundamental vulnerability remains. As long as American tax dollars subsidize high-risk biological research in corners of the world beyond the reach of American inspectors, the next global biological crisis is simply a broken vial away.
